AN2 Therapeutics Inc’s recently made public that its Director Zakrzewski Joseph S unloaded Company’s shares for reported $1.91 million on Jan 18 ’24. In the deal valued at $19.11 per share,100,000 shares were sold. As a result of this transaction, Zakrzewski Joseph S now holds 405,880 shares worth roughly $0.81 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Aziz Kabeer sold 100,000 shares, generating $1,965,000 in total proceeds. Upon selling the shares at $19.65, the Director now owns 377,542 shares.
Before that, Adjuvant Global Health Technol sold 84,093 shares. AN2 Therapeutics Inc shares valued at $1,652,427 were divested by the 10% Owner at a price of $19.65 per share. As a result of the transaction, Adjuvant Global Health Technol now holds 1,995,958 shares, worth roughly $3.99 million.
JMP Securities upgraded its AN2 Therapeutics Inc [ANTX] rating to a Mkt outperform from a a Mkt perform in a research note published recently. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who decreased its forecast for the stock in mid February from “an Outperform” to “a Market perform”. Oppenheimer also remained covering ANTX and has decreased its forecast on February 12, 2024 with a “Perform” recommendation from previously “an Outperform” rating. JMP Securities revised its rating on February 12, 2024. It rated ANTX as “a Mkt perform” which previously was an “a Mkt outperform”.
Price Performance Review of ANTX
On Tuesday, AN2 Therapeutics Inc [NASDAQ:ANTX] saw its stock fall -3.38% to $2.00. Over the last five days, the stock has gained 0.50%. AN2 Therapeutics Inc shares have fallen nearly -90.24% since the year began. Nevertheless, the stocks have fallen -71.43% over the past one year. While a 52-week high of $22.22 was reached on 01/10/24, a 52-week low of $1.91 was recorded on 06/13/24. SMA at 50 days reached $2.31, while 200 days put it at $10.75. A total of 61160.0 shares were traded, compared to the trading of 88300.0 shares in the previous session.
Levels Of Support And Resistance For ANTX Stock
The 24-hour chart illustrates a support level at 1.97, which if violated will result in even more drops to 1.94. On the upside, there is a resistance level at 2.04. A further resistance level may holdings at 2.09. The Relative Strength Index (RSI) on the 14-day chart is 40.37, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.04, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 66.67%. Stochastics %K at 62.96% indicates the stock is a holding.
